Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Utidelone plus capecitabine for active brain metastases in triple-negative advanced breast cancer (phase II, single-arm)
ChiCTR2400088235Phase 2Not yet recruiting
- Sponsor
- Henan Cancer Hospital
- Start
- Aug 2024
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of utidelone and capecitabine in triple-negative breast cancer (TNBC) and brain metastases, sponsored by Henan Cancer Hospital. Primary endpoint: CNS objective response rate (RANO). Planned start Aug 2024; status: not yet recruiting.
02
Drugs
utidelonecapecitabine
03
Conditions
triple-negative breast cancer (TNBC)brain metastases
Beyond the preview
Go deeper on ChiCTR2400088235.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400088235.